Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $269.56 | 9 | 95.5% |
| Education | $12.70 | 1 | 4.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $106.83 | 2 | $0 (2020) |
| Abbott Laboratories | $68.07 | 1 | $0 (2022) |
| Merck Sharp & Dohme LLC | $62.81 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $17.37 | 1 | $0 (2019) |
| Medtronic, Inc. | $13.70 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $13.48 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $19.14 | 1 | Merck Sharp & Dohme LLC ($19.14) |
| 2022 | $81.77 | 2 | Abbott Laboratories ($68.07) |
| 2020 | $43.15 | 2 | GlaxoSmithKline, LLC. ($29.87) |
| 2019 | $61.24 | 4 | Merck Sharp & Dohme Corporation ($30.39) |
| 2017 | $76.96 | 1 | GlaxoSmithKline, LLC. ($76.96) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/15/2022 | Medtronic, Inc. | CRESCENT SPINAL SYSTEM (Device) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: TL | ||||||
| 05/03/2022 | Abbott Laboratories | ENSITE PRECISION (Device) | Food and Beverage | In-kind items and services | $68.07 | General |
| Category: Electrophysiology | ||||||
| 03/04/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: RESPIRATORY | ||||||
| 03/04/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/12/2019 | Novartis Pharmaceuticals Corporation | FEVIPIPRANT (Drug), XOLAIR | Food and Beverage | In-kind items and services | $13.48 | General |
| 11/06/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/05/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Respiratory | ||||||
| 06/05/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/10/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological), BREO, ANORO | Food and Beverage | In-kind items and services | $76.96 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,546 | 1,698 | $401,921 | $41,342 |
| 2022 | 11 | 1,656 | 1,895 | $493,931 | $54,990 |
| 2021 | 6 | 1,605 | 1,819 | $358,262 | $40,821 |
| 2020 | 8 | 1,314 | 1,443 | $320,345 | $36,233 |
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 70 | 129 | $214,011 | $21,343 | 10.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 79 | $48,032 | $7,238 | 15.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 542 | 579 | $37,056 | $3,434 | 9.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 490 | 503 | $34,707 | $3,274 | 9.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 220 | 228 | $23,256 | $1,688 | 7.3% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 19 | 20 | $18,680 | $1,269 | 6.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 13 | $5,387 | $972.79 | 18.1% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 106 | 106 | $10,282 | $936.26 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $2,914 | $545.22 | 18.7% |
| 36620 | Insertion of artery tube for blood sampling or infusion through skin | Facility | 2023 | 13 | 14 | $5,852 | $465.48 | 8.0% |
| 76937 | Ultrasonic guidance for blood vessel access | Facility | 2023 | 14 | 16 | $1,744 | $176.48 | 10.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 95 | 217 | $327,236 | $37,561 | 11.5% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 664 | 728 | $42,224 | $4,338 | 10.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 530 | 555 | $34,965 | $3,606 | 10.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 23 | 30 | $22,620 | $2,665 | 11.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 31 | $17,143 | $2,435 | 14.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 167 | 173 | $16,089 | $1,303 | 8.1% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 111 | 112 | $9,856 | $1,014 | 10.3% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 11 | 15 | $12,735 | $946.50 | 7.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $2,675 | $521.25 | 19.5% |
| 36620 | Insertion of artery tube for blood sampling or infusion through skin | Facility | 2022 | 11 | 12 | $4,560 | $385.14 | 8.4% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 11 | 11 | $3,828 | $215.53 | 5.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 72 | 164 | $247,312 | $29,200 | 11.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 689 | 785 | $45,530 | $4,872 | 10.7% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 535 | 556 | $35,028 | $3,772 | 10.8% |
About Mani Latifi
Mani Latifi is a Critical Care Medicine healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1548587033.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mani Latifi has received a total of $282.26 in payments from pharmaceutical and medical device companies, with $19.14 received in 2023. These payments were reported across 10 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($269.56).
As a Medicare-enrolled provider, Latifi has provided services to 6,121 Medicare beneficiaries, totaling 6,855 services with total Medicare billing of $173,387. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Cleveland, OH
- Active Since 04/23/2010
- Last Updated 07/05/2017
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548587033
Products in Payments
- NUCALA (Biological) $106.83
- ENSITE PRECISION (Device) $68.07
- ZERBAXA (Drug) $62.81
- FASENRA (Drug) $17.37
- CRESCENT SPINAL SYSTEM (Device) $13.70
- FEVIPIPRANT (Drug) $13.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Cleveland
Robert Schilz, Do, DO
Critical Care Medicine — Payments: $356,385
Dr. Bryan Benn, Md, Phd, MD, PHD
Critical Care Medicine — Payments: $102,416
Dr. Charles Lane, M.d, M.D
Critical Care Medicine — Payments: $89,739
Prof. Marcelo Gama De Abreu, Md, MD
Critical Care Medicine — Payments: $25,141
Kingman Strohl, Md, MD
Critical Care Medicine — Payments: $19,097
Rana Hejal, Md, MD
Critical Care Medicine — Payments: $16,502